ArticleEndocrine2025
Long-term surgical outcomes in TSH-secreting pituitary adenomas: the hidden burden of asymptomatic hyperthyroidism.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between the WHO 2017 and 2022 classification updates and ICD-10 code accuracy in patients with PitNETs: a real-world retrospective study.BMC endocrine disorders · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThyrotropin (TSH)-secreting pituitary adenomas, though a rare cause of hyperthyroidism, present significant challenges in management. This study aimed to assess surgical outcomes, remission factors, and postoperative complications.
methodsIn this largest single-center retrospective study, we analyzed 177 TSHoma surgical patients (2001-2022), with 152 cases selected for long-term follow-up. Primary outcome was remission; secondary outcomes included postoperative infection and hypopituitarism.
resultsThe overall remission rate was 72.4%. Radiologically, patients with Knosp Grade 3-4 tumors (OR = 12.95, 95% CI: 3.65-53.77, p < 0.001), suprasellar involvement (OR = 8.61, 95% CI: 2.66-31.37, p < 0.001) significantly elevated the risk of non-remission. Asymptomatic hyperthyroid TSHomas, despite the absence of overt hyperthyroidism symptoms, comprise 24.3% of cases and are characterized by a significantly lower remission rate (54.1%) compared to mild (82.8%) and severe hyperthyroidism (73.7%), accompanied by larger tumor size [26.0 (19.0-30.0) mm], increased cavernous sinus involvement (38.9%), and more extensive suprasellar extension (43.2%). Postoperative TSH level ≤ 0.183 µIU/ml (AUC 0.752, sensitivity 80.0%, specificity 69.7%) and tumor maximum diameter ≤ 21.5 mm remission (AUC 0.858, sensitivity 81.9%, specificity 81.8%) can serve as simple predictors for remission. The rate of postoperative complications was 7.7% for CNS infection and 15.1% for hypopituitarism, respectively. Notably, CSF leakage significantly elevated the risk of postoperative infection (OR = 37.30, 95% CI: 5.58-507.77, p = 0.001) and hypopituitarism (OR = 5.43, 95% CI: 1.67-18.97, p = 0.006).
conclusionSurgical intervention for TSHoma demonstrates a promising remission rate. Asymptomatic TSHomas should be exclusively cautious due to their significantly lower remission rates. CSF leakage correlates with an increased risk of both postoperative infection and hypopituitarism.
Indexed as
Identifiers
40483637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.